The $3.4 Billion Lesson Pharma Faces in Shelved Drugs
Thousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Searching for ways to earn money with little time? Discover effective strategies to make money even with a packed schedule.
23,073 articlesThousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Lawmakers face a looming funding gap in Social Security, with projections of trust fund depletion by the early 2030s....
Chrome is quietly shifting how it handles data with a big on-device AI move and a loosened privacy pledge. This in-de...
Cava Group bets on fresh growth and better margins, even as the market stays wary. This piece breaks down what could ...
Nvidia stock investors just received a wave of bullish commentary from analysts as AI demand powers data centers and ...
IMAX stock jumped this week as takeover chatter surfaced. This article breaks down the drivers behind the move, what ...
Discover FitLife's 2025 earnings story, from revenue drivers to margins and cash flow. This guide breaks down what th...
Dell Technologies could be positioning itself as a key AI infrastructure player. This article dives into the AI drive...
When a top Remitly executive sells shares, investors want to know what it means. This guide explains insider sales, h...
In 2026, XMAG has surged while MAGS has slipped, underscoring a shift from mega-cap AI bets to broad-market exposure....
When cloud stocks tumble, two giants stand out as potential bargains. This guide breaks down whether Oracle or Salesf...
Discover the quiet power of Baupost. This article unpacks Seth Klarman’s patient, risk-aware value approach, how the ...